ExosomeDx empowers the world’s leading biopharma companies in exploring this unique technology.Įxosomes: New Standard In Multi-Analyte Liquid Biopsy TestingĪfter studying in the field of cancer epigenetics, Taylor Jensen, Ph.D. Skog earned his Master of Biomedical Sciences and Doctorate at Umeå University, Sweden.Įxosome Diagnostics, a leader in developing liquid biopsy-based diagnostics, is the first and only company that can simultaneously isolate and analyze exosomal RNA and cfDNA in a single step to achieve highest sensitivity for detecting rare mutations. Skog’s research background includes virology, gene therapy, brain tumors, RNA and biomarker discovery, and he is an inventor on several patents. Skog continues to pioneer critical advancements in diagnostics and expand the field of exosome biology. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. While at Massachusetts General Hospital/Harvard Medical School, Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |